Home » Business News » 2013 » July » July 1, 2013

Galapagos Increases Share Capital Through Warrant Exercises

July 1, 2013 - Mechelen, Belgium

Galapagos NV (EURONEXT BRUSSELS: GLPG)announced today a capital increase arising from employee and managementwarrant exercises.

Since its inception in 1999, Galapagos has used warrant plans toincentivize personnel and management and have them share in the successof the company. Following warrant exercises during the exercise periodrunning from 8 June 2013 through 21 June 2013, Galapagos issued90,143 new ordinary shares on 1 July 2013 for a total capitalincrease (including issuance premium) of EUR584,200.40.

Galapagos' Executive Committee has put a warrant exercise program intoplace whereby Executive Committee members have made a commitment toexercise a fixed number of warrants during subsequent exerciseperiods, subject to certain conditions. During this exercise period,three Executive Committee members exercised warrants for a combinedtotal of 7,500 warrants. CEO Onno van de Stolpe did not exercise anywarrants.

To date, Galapagos' total share capital amounts to EUR160,962,030.82;the total number of securities conferring voting rights is 29,755,302,which is also the total number of voting rights (the "denominator"), andall securities conferring voting rights and all voting rights are of thesame category. The total number of rights (warrants) to subscribe to notyet issued securities conferring voting rights is 3,033,225, which equalsthe total number of voting rights that may result from the exercise ofthese warrants.

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novelmodes-of-action, with a large pipeline of four clinical, sevenpre-clinical, and 30 discovery small-molecule and antibody programsin cystic fibrosis, inflammation, antibiotics, metabolic disease, andother indications.

GLPG0634 is an orally-available, selective inhibitor of JAK1 for thetreatment of rheumatoid arthritis and potentially other inflammatorydiseases, currently in Phase 2B studies in RA and about to enterPhase 2 studies in Crohn's disease. AbbVie and Galapagos signed aworldwide license agreement whereby AbbVie will be responsible forfurther development and commercialization after Phase 2B. Galapagos hasanother selective JAK1 inhibitor in Phase 2 in lupus and psoriasis,GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012).GLPG0187 is a novel integrin receptor antagonist currently in a Phase 1Bpatient study in metastasis. GLPG0974 is the first inhibitor of FFA2 tobe evaluated clinically for the treatment of IBD; this program iscurrently in a Proof of Concept Phase 2 study.

The Galapagos Group, including fee-for-service companies BioFocus,Argenta and Fidelta, has 800 employees and operates facilities infive countries, with global headquarters in Mechelen, Belgium. Furtherinformation at:

This release may contain forward-looking statements, including,without limitation, statements containing the words "believes,""anticipates," "expects," "intends," "plans," "seeks," "estimates,""may," "will," "could," "stands to," and "continues," as well assimilar expressions. Such forward-looking statements may involve knownand unknown risks, uncertainties and other factors which might cause theactual results, financial condition, performance or achievements ofGalapagos, or industry results, to be materially different from anyhistoric or future results, financial conditions, performance orachievements expressed or implied by such forward-looking statements.Given these uncertainties, the reader is advised not to place any unduereliance on such forward-looking statements. These forward-lookingstatements speak only as of the date of publication of this document.Galapagos expressly disclaims any obligation to update any suchforward-looking statements in this document to reflect any change in itsexpectations with regard thereto or any change in events, conditions orcircumstances on which any such statement is based, unless required by lawor regulation.

This announcement is distributed by Thomson Reuters on behalf of ThomsonReuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and otherapplicable laws; and

(ii) they are solely responsible for the content, accuracy and originalityof the information contained therein.

Source: Galapagos NV via Thomson Reuters ONE



Elizabeth Goodwin
Director Investor Relations
Tel: +31 6 2291 6240
Email Contact


Comment on this story